<- Go Home
Aroa Biosurgery Limited
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
Market Cap
AUD 221.0M
Volume
313.9K
Cash and Equivalents
AUD 10.4M
EBITDA
AUD 3.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
AUD 76.9M
Profit Margin
85.07%
52 Week High
AUD 0.97
52 Week Low
AUD 0.46
Dividend
N/A
Price / Book Value
2.39
Price / Earnings
-120.39
Price / Tangible Book Value
2.81
Enterprise Value
AUD 204.4M
Enterprise Value / EBITDA
40.62
Operating Income
AUD 630.0K
Return on Equity
1.97%
Return on Assets
0.37
Cash and Short Term Investments
AUD 23.6M
Debt
AUD 7.0M
Equity
AUD 92.4M
Revenue
AUD 90.4M
Unlevered FCF
AUD 4.8M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium